#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Dermatitis atopic Dementia Alzheimer's type Asthma Breast cancer metastatic Type 2 diabetes mellitus Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    White matter lesion Bulbospinal muscular atrophy congenital Hereditary hypophosphataemic rickets Hepatitis B Brain abscess Hyperoxaluria Cold type haemolytic anaemia Oesophageal carcinoma Chronic graft versus host disease in liver Waldenstrom's macroglobulinaemia refractory Idiopathic intracranial hypertension Ovarian cancer stage IV Mastocytosis Familial dilated cardiomyopathy Erythema multiforme More trials…

    Learn about Rare Diseases

    Proteus syndrome – Basic Information Behcet’s syndrome – Diagnostics Lymphangiosarcoma – Treatment Rosai-Dorfman syndrome – Trials in Disease Gaucher’s disease type I – Treatment Familial amyotrophic lateral sclerosis Pleural mesothelioma malignant – Trials in Disease Leiomyosarcoma recurrent – Life with Disease Mantle cell lymphoma stage II – Diagnostics Ocular melanoma – Diagnostics More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Prednisolone Sodium Succinate Calcium Elamipretide Trihydrochloride Emiplacel Oxygen Ph.eur. Gefurulimab DICLOFENAC POTASSIUM Cetirizine Dihydrochloride Brimonidine Tartrate Vb10.16 Cisatracurium Besilate Fingolimod Hydrochloride Methyl Aminolevulinate Eo2318 Betamethasone Sodium Phosphate Garadacimab D-Biotin PUCOTENLIMAB Golodirsen Ddcart‐Cd19 More therapies…

    Learn about Your Condition

    Hypothyroidism Infertility male Nasopharyngeal cancer Loeys-Dietz syndrome Retinoblastoma Pneumonia chlamydial Retroperitoneal cancer Tuberculosis Penile squamous cell carcinoma Malignant peritoneal neoplasm Ovarian cancer metastatic Meningioma malignant Essential hypertension Infertility female Biliary tract disorder More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Landeskrankenanstalten-Betriebsgesellschaft Kabeg

Landeskrankenanstalten-Betriebsgesellschaft Kabeg

Feschnigstrasse 11, Klagenfurt,09.Bez.:Annabichl, Klagenfurt am Wörthersee, 9020, Austria

Want to learn more about this study or check if you can participate? Contact us.

  • Study on Dabigatran and Phenprocoumon for Treating Left Ventricular Thrombosis After Heart Attack in Patients with STEMI

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Cardiac ventricular thrombosis
    • Acute myocardial infarction
    Investigated Drugs:
    • Dabigatran Etexilate
    • Phenprocoumon
    • Acetylsalicylic Acid
    Austria

  • Study Comparing Chemotherapy Alone to Chemotherapy with Nivolumab or Nivolumab and BMS-986205 for Patients with Muscle-Invasive Bladder Cancer

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Bladder cancer
    Investigated Drugs:
    • Cisplatin
    • Gemcitabine Hydrochloride
    • Nivolumab
    Austria Belgium Finland France Germany Greece +5

  • Study of Atezolizumab and Bevacizumab for Patients with High-Risk Hepatocellular Carcinoma After Surgery or Ablation

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Atezolizumab
    • Bevacizumab
    Austria Belgium Czechia France Germany Italy +3

  • Study Comparing Adagrasib and Docetaxel for Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Adagrasib
    • Docetaxel
    Austria Belgium Czechia France Germany Greece +8

  • Study on the Effectiveness and Safety of Bevacizumab, Atezolizumab, and RO7247669 in Patients with Resectable Liver Cancer

    Not recruiting

    1 1 1 1
    Investigated Drugs:
    • Ro7247669
    • Atezolizumab
    • Bevacizumab
    Austria France Germany Spain

  • Study on the Effectiveness and Safety of AP707 and Naproxen for Patients with Chronic Back Pain

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Back pain
    Investigated Drugs:
    • Aceclofenac
    • Acemetacin
    • Acetylsalicylic Acid
    Austria Germany

  • Study of Datopotamab Deruxtecan and Pembrolizumab for Patients with Advanced Non-Small Cell Lung Cancer with Low PD-L1 Levels

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Non-small cell lung cancer
    Investigated Drugs:
    • Carboplatin
    • Cisplatin
    • Datopotamab Deruxtecan
    Austria Belgium Czechia France Germany Greece +7

  • Study on the Effectiveness of AP707, Gabapentin, and Capsaicin for Patients with Chronic Pain from Traumatic or Post-Operative Peripheral Neuropathy

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Neuropathy peripheral
    • Pain
    Investigated Drugs:
    • Adezunap
    • Amitriptyline
    • Buclizine Hydrochloride
    Austria Germany

  • Study on the Effectiveness and Safety of AP707 with Lamotrigine and Amitriptyline for Patients with Chronic Central Neuropathic Pain

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Neuropathy peripheral
    • Pain
    Investigated Drugs:
    • Adezunap
    • Amitriptyline
    • Buclizine Hydrochloride
    Austria Germany

  • Study Comparing ARV-471 and Fulvestrant for Patients with Advanced Estrogen Receptor-Positive, HER2-Negative Breast Cancer After Endocrine Treatment

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Breast cancer
    Investigated Drugs:
    • (3S)-3-[6-[4-[[1-[4-[(1R,2S)-6-Hydroxy-2-Phenyl-1,2,3,4-Tetrahydronaphthalen-1-Yl]Phenyl]Piperidin-4-Yl]Methyl]Piperazin-1-Yl]-3-Oxo-1H-Isoindol-2-Yl]Piperidine-2,6-Dione
    • Fulvestrant
    Austria Belgium Bulgaria Czechia Finland France +9
Previous Page
1 … 3 4 5 6
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!